纳络酮预防早产儿原发性呼吸暂停32例

The prevention of primary apnea in prematurity with naloxone

目的:探讨纳络酮预防早产儿原发性呼吸暂停的疗效。方法:将胎龄≤34周的早产儿62例随机分为两组,对照组30例出生后立即给予氨茶碱3mg/kg加入10% GS 15mL静脉滴注,3次/d,治疗组32例出生后即在给予氨茶碱的基础上加用纳络酮0.1mg/(kg·次)静脉推注,3次/d,72h或120h观察结果。结果:治疗组发生原发性呼吸暂停的次数(2.8±0.9)较对照组(3.8±1.2)减少(t=3.38,P<0.01),持续时间(28.7±4.17)s较对照组(34.7±5.2)s缩短(t=3.4,P<0.01)。结论:纳络酮预防早产儿原发性呼吸暂停疗效显著,未见明显不良反应,建议对≤34周早产儿出生后常规应用纳络酮,可降低原发性呼吸暂停发生率,改善预后。

Objective：To prevent premature newborns from primary apnea with naloxone. Methods：62 cases of prematurity ≤34 w gestational age were randomly divided into two groups ： the control group of 30 eases whom were given, intravenously, 10% GS 15 mL plus aminophylline 3 mg/kg three times a day immediately after birth and the treatment group of 32 cases whom were given naloxone 0.1 mg/kg intravenously three times a day besides the amniophylline therapy. The therapeutic effects were evaluated after 72 hours or 120 hours. Results ： The frequency and duration of apnea in the treatment group were less than that of the control group and the difference between the two groups were significant （ P 〈 0.01 ）. Conclusions： The preventive effect of naloxone in prematurity with primary apnea is excellent. No side effect is observed.